Manufacturability by Design: Strategic Insights for Bispecific Antibodies
Bispecific programmes rarely fail at the CDMO. They fail because of decisions taken in candidate selection and cell line development months earlier. This briefing traces late-stage manufacturing failure back to its upstream origins, maps the service ecosystem that has grown up to prevent it, and sets out how sponsors should vet a development partner.
What this report answers
- Why do bispecific programmes fail in late-stage manufacturing when the molecule looked stable in discovery?
- Which decisions in candidate selection and cell line development lock in risk that cannot be fixed downstream?
- What is the difference between an upstream technology enabler and a CDMO, and when does a sponsor need each?
- Which proprietary chain-pairing and cell line platforms do the major CDMOs actually own?
- What should a sponsor probe for when vetting a bispecific development partner?
- Which single hire does most to de-risk a complex biologics portfolio?
10-25%
the share of total expressed protein that can end up as functional drug when chain assembly goes wrong - the yield problem the briefing attributes to mispairing rather than to process.
100+
the number of molecular formats a bispecific sponsor can choose between, which the briefing identifies as the single most consequential manufacturability decision in the programme.
What the analysis establishes
Why bispecifics break the mould
The briefing sets out the three structural problems that separate a bispecific from a conventional antibody: correct assembly of multiple polypeptide chains inside one host cell, a heightened tendency to aggregate, and the cost consequences of expression titres well below mAb norms. It establishes how each one propagates into purification difficulty, safety risk and cost of goods.
Where the failure actually starts
It traces low titre, genetic instability and poor product quality back to two upstream decisions: the molecular format chosen at candidate selection, and how cell line development was run. The section establishes which of these are locked in at the genetic level, why they cannot be recovered downstream, and what shortcuts under timeline pressure typically cost a programme.
The developability standard
The briefing defines developability as the bridge between discovery and CMC, and sets out the measurable property categories a full assessment covers, together with the analytical methods used for each. It also describes the design-build-test-learn loop, and where in silico prediction, DNA synthesis and high-throughput screening now sit within it.
Two kinds of partner, two kinds of risk
The service landscape is assessed in two halves: upstream enablers selling platforms, engineering and cell line technology, and integrated technology CDMOs that now compete on proprietary science rather than capacity alone. Each named provider is described by what it actually solves, including the specific chain-pairing, expression and gene integration platforms behind the marketing names.
How to vet a development partner
A structured due diligence framework organised around five red flags. It covers host cell line characterisation and stability evidence, gene integration technology, early-stage analytical capability, regulatory track record for platform-supported filings, and commercial model alignment. Each flag comes with the question to ask and the evidence a credible partner should be able to produce.
The hire that carries the risk
The briefing profiles the leader it considers the most consequential hire for a complex biologics portfolio, contrasting the early-stage translational profile against the late-stage operational one on mandate, KPIs and attitude to change. It sets out the technical background, translational skills and track record the role demands, and where the market for it is thin.
How it was built
A synthesis of public sources, current as of Q3 2025. The report works from company platform disclosures, licensing and partnership deals, published case studies and public regulatory events, then organises them into a single argument about where bispecific manufacturing risk originates. Provider assessments describe stated capability rather than benchmarked performance. The due diligence framework and the leadership profile are ProGen Search's own, drawn from search work in the modality.
Written for biotech CEOs and CFOs, heads of CMC and process development, investors running diligence on biologics assets, and CDMO commercial and technical leadership.
Contents
- Part A: Strategic Executive Summary
- The Manufacturability Gauntlet: Why Bispecifics Break the Mold
- The Upstream Origin of Downstream Failure
- The 'Manufacturability by Design' Paradigm Shift
- The Service Ecosystem: A Competitive Assessment
- The Sponsor's Due Diligence Playbook: 5 Red Flags When Vetting a Partner
- The Talent Solution: Profiling the "Translational CMC" Linchpin
- Strategic Outlook and Future Trends
- Macro-Level Implications for C-Suite and Investors
Organisations covered
ATUM, Twist Bioscience, Alloy Therapeutics, Xencor, GenScript, Abzena, MacroGenics, Merus, Affimed, Zymeworks, Genmab, Genentech, Harbour BioMed, Lonza, Samsung Biologics, Catalent, WuXi Biologics, FUJIFILM Diosynth Biotechnologies, Boehringer Ingelheim BioXcellence, KBI Biopharma, Celonic Group, ProBioGen, Just-Evotec Biologics, AGC Biologics, Amgen
The full 12-page briefing is free. Tell us where to send it and it downloads immediately.
The State of ADCs 2026
This briefing stops where bispecifics meet conjugate chemistry. The flagship ADC report takes the adjacent modality in full: pipeline, capacity and the operators behind it.
See the full report →